Oct. 5, 2020
by Amandeep Singh
Biopharma insight
The pharmaceutical business is one of the riskiest industries to venture into. Drug discovery is an artisanal process where a …
Sept. 28, 2020
by Andrii Buvailo
Interview
Recently, COVAXX announced it would soon enter human trials as the company is focused on rapidly developing a Multitope Peptide-based …
Sept. 25, 2020
by Andrii Buvailo
Interview
Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company …
Sept. 18, 2020
by Andrii Buvailo
Interview
The application of next-generation data analytics tools, powered by machine learning and artificial intelligence (AI) components, has become a long-term …
Sept. 14, 2020
by Raj Indupuri
Biopharma insight
How life sciences companies are reimagining trials during the biggest health crisis in a century Whatever the world was like …
Sept. 5, 2020
by Patrick Bailey
Biopharma insight
In the "data age," an estimated 81% of Americans own at least one smartphone. That might lead one to wonder …
Aug. 18, 2020
by Ivan Kondratov
Biopharma insight
Recently my favorite website ENDPOINTSNEWS published a rating of key players in the ongoing COVID-19 vaccine race. Compared to many …
July 22, 2020
by Andrii Buvailo
Interview
While the history of Artificial Intelligence (AI) field began in the distant 1950s, its practical value had largely remained limited …
July 11, 2020
by Andrii Buvailo
Biopharma insight
What do antibiotic-resistant bacteria (“superbugs”) and coronaviruses have in common? They both can kill lots of people globally, and they …
July 8, 2020
by Andrii Buvailo
Biopharma insight
The ongoing COVID19 crisis forced biotech-oriented venture capitalists (VC) to somewhat slow down the pace of their usual deal-flow -- …
July 2, 2020
by Andrii Buvailo
Interview
Biopharma companies are now racing to find much-needed cures against SARS-CoV-2, a virus that caused the largest global pandemic of …
July 1, 2020
by David Shlaes
Biopharma insight
(This post originally appeared on David Shlaes's personal blog) The US FDA just published an analysis of antibiotic development looking back …